Cargando…
Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model
Glioblastoma (GBM) is a common and aggressive brain cancer that accounts for 60% of adult brain tumors. Anti-angiogenesis therapy is an attractive option due to the high vasculature density of GBM. However, the best-known anti-angiogenic therapeutics, bevacizumab, and aflibercept, have failed to sho...
Autores principales: | Zhao, Peng, Anami, Yasuaki, Gao, Peng, Fan, Xuejun, Li, Leike, Tsuchikama, Kyoji, Zhang, Ningyan, an, Zhiqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993059/ https://www.ncbi.nlm.nih.gov/pubmed/35388745 http://dx.doi.org/10.1080/19420862.2022.2057269 |
Ejemplares similares
-
Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
por: Anami, Yasuaki, et al.
Publicado: (2018) -
Homogeneous antibody–angiopep 2 conjugates for effective brain targeting
por: Anami, Yasuaki, et al.
Publicado: (2022) -
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma
por: Martini, Maurizio, et al.
Publicado: (2018) -
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
por: Yamazaki, Chisato M., et al.
Publicado: (2021) -
Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors
por: Anami, Yasuaki, et al.
Publicado: (2022)